StockIQ.techSino Biopharmaceutical Limited (1177.HK) Stock Analysis
Free AI-powered analysis and research for Sino Biopharmaceutical Limited stock
Sector: Healthcare
1177.HK snapshot
Data as of 3 Nov 2026 close. Updated daily.
Sino Biopharmaceutical Limited scores 2/100 on StockIQ's model, which reads as strongly negative signals overall. The price is below its 200-day average and at 21% of its 52-week range, down 29.9% over the past year. Latest reported figures show a profit margin of 7.1%, return on equity of 14.1% and revenue growth of +10.6%.
What is driving the score
- Strong Downtrend: -12
- MACD Bearish: -8
- High P/E (32.3): -10
- Long-term Downtrend: -8
- Severe Underperformance (-29.9% over 1 year): -10
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 1177.HK report
Sino Biopharmaceutical Limited (1177.HK) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 1177.HK Now →📰 Latest Update
Sino Biopharmaceutical (SEHK:1177) Stock Looks Expensive On Its Current Earnings
Tue, October 20, 2026 at 6:09 PM UTC 4 min read
Sino Biopharmaceutical (SEHK: 1177) has been flagged as potentially overvalued based on its current earnings, raising concerns among investors about its stock price sustainability. Analysts suggest that the company's high valuation may not be justified given its earnings performance, which could lead to a reevaluation of its market position. Investors should consider these factors when assessing the stock's future prospects and potential risks.